Fair Value Calculator Fair Value Calculator
EN DE

Medi-Caps Limited (523144) Fair Value & Analysis

Other · IN · Market cap ₹280M

MC Medi-Caps Limited 523144 · BSE
Price₹25.93
Fair Value₹34.62
Upside+33.5%
Quality43/100
Watch Medi-Caps Limited for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range ₹22.85 – ₹43.28

Fair value as of: Jul 4, 2026

From 1 valuation models · updated today

Share price −11.0% over the past month.

Price vs Fair Value (12 months)

₹44.57 ₹21.86 Fair Value ₹34.62 Jul 2025 Jul 2026

12‑month range ₹21.86 – ₹44.57 · fair‑value band ₹22.85 – ₹43.28 · the ₹25.93 price screens below the ₹34.62 fair value. As of Jul 4, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Medi-Caps Limited (523144) currently trades at ₹25.93, while our model-based Fair Value estimate is ₹34.62 — implying the stock looks roughly 33.5% undervalued today. We read business quality at 43/100 (below-average quality), in the Other sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, Medi-Caps Limited generated revenue of ₹422M at a net margin of -10.4%. Revenue declined 20.9% year over year. The stock trades on a trailing P/E of 29.3. Fundamentals as of Jul 4, 2026

Key figures & financial health

Revenue (TTM) ₹422M
Revenue growth (YoY) -20.9%
Net margin -10.4%
Free cash flow −₹78.7M FY2026
P/E ratio 29.3
Operating margin -9.7%
More key figures
EPS (TTM) ₹1.10
Net debt ₹619K FY2020

Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.

About the company

Medi-Caps Limited manufactures and sells empty hard gelatin capsule shells in India. It offers halal gelatin, liquid fill, sodium lauryl sulfate free, and preservative free capsules. The company was incorporated in 1983 and is based in Indore, India.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Medi-Caps Limited reported revenue of ₹124M in FY2026 versus ₹699M in FY2022, a compound −35.1%/yr. Reported net income was −₹30.4M in FY2026.

Revenue −35.1%/yr
FY22 ₹699M
FY23 ₹494M
FY24 ₹273M
FY25 ₹255M
FY26 ₹124M
Net income
FY22 ₹101M
FY23 ₹17.6M
FY24 −₹22.4M
FY25 −₹5.7M
FY26 −₹30.4M

Is 523144 fairly valued? → Check now

Similar stocks

6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).

Stock Price Fair Value vs Fair Value
There MOH €521.90 €209.16 -60%
Sony Corporation SON1 €17.58 €37.56 +114%
Federal Home Loan Mortgage Corporation FREJO $16.84 $28.75 +71%
533278 533278 ₹438.60 ₹720.31 +64%
Nestl?? India Limited 500790 ₹1,459 ₹279.60 -81%
540376 540376 ₹3,993 ₹1,806 -55%

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Medi-Caps Limited (523144) undervalued?
As of Jul 4, 2026, our model estimates a fair value of ₹34.62 versus a price of ₹25.93 — about +34% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 523144?
Our model-based fair value for Medi-Caps Limited is ₹34.62 (as of Jul 4, 2026), built from audited fundamentals. The current price is ₹25.93.
What is the quality score of 523144?
Medi-Caps Limited has a Quality Score of 43/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Medi-Caps Limited (523144)?
Medi-Caps Limited reported trailing-twelve-month revenue of about ₹422M (latest available figure, as of Jul 4, 2026).
What is the net profit margin of 523144?
The net profit margin of Medi-Caps Limited is about -10.4%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.